Secondary antibody deficiencies

Curr Opin Allergy Clin Immunol. 2015 Dec;15(6):505-13. doi: 10.1097/ACI.0000000000000215.

Abstract

Purpose of review: Antibody deficiency can occur in the context of primary immune deficiency due to inherited genetic defects or secondary to a variety of causes. This review aims to summarize current data concerning the causes of secondary antibody deficiency and where possible evidence regarding the use of prophylactic replacement immunoglobulin. (Figure is included in full-text article.)

Recent findings: Advances in immune-mediated therapies ranging from monoclonal antibodies to novel B-cell-targeted therapeutics are responsible for an expansion in the possible iatrogenic causes of antibody deficiency.

Summary: Causes of secondary antibody deficiency include B-cell lymphoproliferative disease, notably chronic lymphocytic leukaemia and multiple myeloma, protein losing states, disorders of lymphatic circulation, increased immunoglobulin catabolism and a growing number of therapeutic agents. At-risk patients should be closely monitored for the development of hypogammaglobulinaemia, B-cell function should be defined where appropriate with specific antibody responses to immunization antigens and where there is a significant burden of infections patients should be treated with prophylactic antibiotics and/or replacement immunoglobulin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibiotic Prophylaxis
  • B-Lymphocytes / immunology*
  • Humans
  • Iatrogenic Disease / prevention & control*
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunologic Deficiency Syndromes / etiology
  • Immunologic Deficiency Syndromes / prevention & control*
  • Infections / complications
  • Infections / drug therapy
  • Infections / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / immunology*

Substances

  • Immunoglobulins, Intravenous